Bristol Myers Is the Most at Risk From a Revenue Perspective

Mizuho Healthcare Strategist, Jared Holtz says drug companies face imminent price declines. He also expects deal-making in the sector to heat up as companies face imminentprice declines. "It's really a conversation we're going to be having in perpetuity or at least for the next few years into the end of the decade," he said.